REG - Imaging Biometrics - IB Announces Soft Close to Phase 1 Trial
21/07/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250721:nRSU8287Ra&default-theme=true
RNS Number : 8287R Imaging Biometrics Limited 21 July 2025
Imaging Biometrics Limited
("IB" or the "Company")
Imaging Biometrics Announces Soft Close to Phase 1 Trial of Oral Gallium
Maltolate for Relapsed or Refractory Glioblastoma
Elm Grove, WI - July 21, 2025 - Imaging Biometrics, LLC, a leader in
quantitative imaging and novel therapeutics for CNS malignancies, today
announces a soft close to its Phase 1 clinical trial of oral gallium maltolate
(GaM) in adult relapsed or refractory glioblastoma. The trial remains active
for currently enrolled participants, with no additional patients being
recruited at this time.
This milestone reflects strong early engagement and sufficient enrollment to
meet the trial's statistical and operational objectives. While final internal
approvals from the Medical College of Wisconsin Cancer Center are pending, the
soft close enables the trial team to transition toward data consolidation,
endpoint analysis, and Phase 2 protocol finalization - key steps in advancing
the development of oral GaM.
Oral GaM offers a differentiated therapeutic profile: once-daily, at-home
dosing, a favorable safety record, and a novel mechanism of action that
disrupts iron metabolism in tumor cells. With excellent tolerability, GaM is
positioned as a potentially transformative agent in glioblastoma care.
IB is actively evaluating the feasibility of independently financing the phase
2 trial while concurrently exploring strategic partnerships. The Company will
provide further updates as the trial progresses toward formal closure and data
dissemination.
The Board thanks its investigators, its collaborators at the Medical College
of Wisconsin, and the patients who continue to drive this research forward.
--ENDS-
The Directors of the Company accept responsibility for the contents of this
announcement.
For further information, please contact:
Imaging Biometrics Ltd
Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Tel: 020 7220 9797
About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of Imaging
Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
Imaging Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on X, @ImgBiometrics.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END STRPPUMCMUPAPGU